Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

667
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
667
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

18.1K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discrimination of atrial fibrillation burden using cardiac magnetic resonance imaging.

Heart rhythm O2·2026
Same author

Genetic Cascade Screening for Familial Hypercholesterolemia: A Randomized Clinical Trial.

JAMA network open·2026
Same author

Decoding sex and gender effects on health: evidence from a nationwide cohort.

Biology of sex differences·2026
Same author

Serum Neurofilament Light Chain and Cardiovascular Outcomes in Patients With Atrial Fibrillation.

JAMA cardiology·2026
Same author

Hospital@Home: improving discharge management and reducing the risk of rehospitalizations in multimorbid Patients - Protocol for a randomized clinical trial.

Trials·2026
Same author

Ischemic brain infarcts, white matter hyperintensities, and cognitive impairment are increased in patients with Atrial Fibrillation.

Communications medicine·2026

Related Experiment Video

Updated: Dec 17, 2025

New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells
06:34

New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells

Published on: October 9, 2017

9.4K

Apelin-potential therapy for COVID-19?

Seyed Soheil Saeedi Saravi1, Jürg H Beer1

  • 1Center for Molecular Cardiology, University of Zurich, 8952 Schlieren, Switzerland; Department of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland.

Journal of Molecular and Cellular Cardiology
|June 21, 2020
PubMed
Summary
This summary is machine-generated.

Apelin receptor agonists show promise for treating COVID-19 complications. These therapies may improve acute lung injury and cardiovascular issues by modulating the renin-angiotensin system, offering new therapeutic avenues.

Keywords:
ApelinCOVID-19Renin-angiotensin system

More Related Videos

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

1.2K
In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses
12:23

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

Published on: September 7, 2022

2.0K

Related Experiment Videos

Last Updated: Dec 17, 2025

New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells
06:34

New Application of an Atmospheric Pressure Plasma Jet as a Neuro-protective Agent Against Glucose Deprivation-induced Injury of SH-SY5Y Cells

Published on: October 9, 2017

9.4K
Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

1.2K
In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses
12:23

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

Published on: September 7, 2022

2.0K

Area of Science:

  • Medical Research
  • Pharmacology
  • Infectious Diseases

Background:

  • COVID-19 presents significant risks of lung injury and cardiovascular complications, including coagulopathies.
  • The renin-angiotensin system (RAS) plays a critical role in the pathophysiology of these COVID-19-related complications.
  • Current therapeutic strategies primarily focus on blocking viral entry or drug repurposing, necessitating exploration of alternative treatments.

Purpose of the Study:

  • To investigate the therapeutic potential of apelin or its receptor agonists for managing COVID-19-associated lung injury and cardiovascular/coagulopathy complications.
  • To explore the mechanisms by which apelin agonists may counteract the detrimental effects of the renin-angiotensin system in COVID-19.

Main Methods:

  • This study proposes a theoretical framework based on existing knowledge of the renin-angiotensin system and apelin signaling.
  • The proposed mechanism involves the modulation of key RAS components, including angiotensin-converting enzyme (ACE), angiotensin II (Ang-II), angiotensin receptor 1 (AT1R), and ACE2.

Main Results:

  • Apelin or its receptor agonists demonstrate potential in suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production.
  • These agents may down-regulate angiotensin receptor 1 (AT1R) and mitigate ACE2 up-regulation.
  • The therapeutic approach could lead to an improved Angiotensin II/Angiotensin (1-7) ratio, crucial for mitigating COVID-19 complications.

Conclusions:

  • Apelin and its receptor agonists represent a promising therapeutic strategy for patients suffering from lung injury and cardiovascular/coagulopathy complications associated with COVID-19.
  • Targeting the apelin system offers a novel approach to managing the severe manifestations of COVID-19 by rebalancing the renin-angiotensin system.